Bottom line
FBTAX vs FBDIX: the short answer
FBTAX (Fidelity Advisor Biotechnology Fund) and FBDIX (Franklin Biotechnology Discovery Fund) are quite different portfolios: only about 39% of their top holdings (by weight) are shared.
FBTAX is cheaper at 0.94% vs 1.01% — a difference of $7.00 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs +5.0% for FBDIX (reporting dates differ).
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
FBTAX vs FBDIX side by side
| FBTAX | FBDIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.94% | 1.01% |
| Annual cost per $10k | $94 | $101 |
| 10-yr cost on $10k (prospectus) | $1,663 | $1,728 |
| Max front load | — | 5.5% |
| 12b-1 fee | 0.25% | 0.25% |
| 1-yr return | +31.5% | +43.9% |
| 5-yr return (annualized) | +6.4% | +5.0% |
| 10-yr return (annualized) | +7.7% | +6.4% |
| Best quarter | +30.3% | +29.5% |
| Worst quarter | −27.8% | −24.5% |
| Net assets (fund) | $2.2B | $1.2B |
| Number of holdings | 129 | 126 |
| Portfolio turnover | 54% | 38% |
| Returns as of | Sep 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBTAX | FBDIX | Difference |
|---|---|---|---|
| 2025 | +39.6% | +52.3% | −12.8% |
| 2024 | +5.3% | +4.0% | +1.3% |
| 2023 | +10.7% | +18.4% | −7.7% |
| 2022 | −8.0% | −12.7% | +4.7% |
| 2021 | −3.6% | −17.7% | +14.1% |
| 2020 | +32.2% | +29.9% | +2.3% |
| 2019 | +25.7% | +34.8% | −9.1% |
| 2018 | −3.8% | −15.7% | +11.9% |
| 2017 | +25.8% | +18.8% | +7.0% |
| 2016 | −23.6% | −17.2% | −6.4% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FBTAX's top 25 holdings also appear in FBDIX's top 25.
| Holding | FBTAX | FBDIX |
|---|---|---|
| Gilead Sciences Inc | 5.70% | 3.86% |
| Spyre Therapeutics Inc | 3.83% | 1.87% |
| Dianthus Therapeutics Inc | 3.55% | 2.32% |
| Oruka Therapeutics Inc | 3.24% | 1.86% |
| Insmed Inc | 3.05% | 1.99% |
| Revolution Medicines Inc | 3.00% | 3.01% |
| Argenx Se | 3.00% | 3.62% |
| Ascendis Pharma A/s | 2.99% | 2.56% |
| Amgen Inc | 2.37% | 4.39% |
| Amylyx Pharmaceuticals Inc | 2.25% | 1.32% |
| Vertex Pharmaceuticals Inc | 1.39% | 3.54% |
Source: SEC Form N-PORT
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between FBTAX and FBDIX?
Which is cheaper, FBTAX or FBDIX?
Should I own both FBTAX and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.